BCRX BioCryst Pharmaceuticals, Inc. - Common Stock
$9,88
Harga · Agu 18, 2026
Fundamental per Agu 5, 2026
Rentang 52M
$6–$11
74% of range
Peringkat Analis
BUY
17 analysts
Target Harga
$21
+111% upside
P/E (TTM)
9.7
ROE
-97.6%
Margin Laba Bersih
30.2%
Tentang BioCryst Pharmaceuticals, Inc. - Common Stock Tinjauan perusahaan dari Wikipedia
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.
Baca selengkapnya
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.
History
The company was founded in 1986 by Charles E. Bugg and John A. Montgomery. In March 1994, BioCryst became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In 2008, the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.
In October 2010, BioCryst announced its headquarters would move to Durham, North Carolina, where the company has had an office since 2006. In January 2018, BioCryst signed a definitive merger agreement with Idera Pharmaceuticals, with plans for the combined company to change its name and move to Pennsylvania. However, BioCryst shareholders voted down the merger in July.
Pipeline
BioCryst’s core development programs include:
Berotralstat (BCX7353), an oral inhibitor of plasma kallikrein for prevention and treatment of hereditary angioedema (HAE).
FDA has approved Expanded Access Program for berotralstat for eligible patients in the United States.
Berotralstat has a PDUFA date for FDA approval on December 3, 2020.
On December 3, 2020, the FDA approved berotralstat as the first oral hereditary angioedema prophylaxis.
BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases.
FDA has granted Fast Track designation for BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
BCX9250, an oral ALK-2 inhibitor for treatment of fibrodysplasia ossificans progressiva (FOP).
Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses including SARS-CoV-2 (the cause of COVID-19), Ebola, Marburg, Yellow Fever and Zika.
Galidesivir was safe and generally well tolerated in Phase 1 clinical safety and pharmacokinetics trials conducted in 2019 by both intravenous and intramuscular routes of administration in healthy human subjects.
In animal studies, galidesivir has demonstrated survival benefits against a variety of serious pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses.
BioCryst is developing galidesivir in collaboration with U.S. government agencies and other institutions.
In September 2013, NIAID contracted with BioCryst for the development of galidesivir as a treatment for Marburg virus disease and potentially for other filoviruses, including Ebola virus.
In March 2015, BioCryst announced that the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health & Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) has awarded BioCryst a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses.
In April 2020, BioCryst began enrollment of a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19. This clinical trial is (NCT03891420) is being funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The company later made the decision to cease conducting further trials.
Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗
BCRX Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
Harga
$9.88
Kapitalisasi Pasar
$2.51B
P/E (TTM)
9.7
EPS (TTM)
$1.21
Pendapatan (TTM)
$875M
Imbal Hasil Dividen
—
ROE
-97.6%
D/E Utang/Ekuitas
0.0
Rentang 52M
$6 – $11
BCRX Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
Configure
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Pendapatan & Laba Bersih
$875M
2016-12-31
→
2025-12-31
EPS
$1.21
2020-12-31
→
2025-12-31
Arus Kas Bebas
$345M
2016-12-31
→
2025-12-31
Margin
30.2%
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
Metrik
Tren 5 Tahun
BCRX
Median Rekan
P/E (TTM)
9.7
97.6
P/S (TTM)
2.9
7.7
P/B
-21.1
8.0
EV / EBITDA
6.5
—
Price / FCF (Harga / FCF)
7.3
—
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
Metrik
Tren 5 Tahun
BCRX
Median Rekan
Operating Margin (Margin Operasi)
39.0%
—
Net Profit Margin (Margin Laba Bersih)
30.2%
-51.7%
ROA
52.5%
-44.2%
ROE
-97.6%
-63.5%
ROIC
-282.4%
—
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
Metrik
Tren 5 Tahun
BCRX
Median Rekan
Debt / Equity (Utang / Ekuitas)
0.0
18.7
Current Ratio (Rasio Lancar)
2.1
4.9
Quick Ratio (Rasio Cepat)
1.9
—
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
Metrik
Tren 5 Tahun
BCRX
Median Rekan
Revenue YoY (Pendapatan YoY)
94.1%
—
Revenue CAGR 3Y (CAGR Pendapatan 3T)
47.8%
—
Revenue CAGR 5Y (CAGR Pendapatan 5T)
117.9%
—
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
Metrik
Tren 5 Tahun
BCRX
Median Rekan
BCRX Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
BELI
17 analis
- Beli Kuat 5 29,4%
- Beli 10 58,8%
- Tahan 2 11,8%
- Jual 0 0,0%
- Jual Kuat 0 0,0%
Target Harga 12 Bulan
11 analis · 2026-08-17
Median
$17.00
Rata-rata
$20.82
← Di bawah semua target
$9.88
Rendah
$12.00
Tinggi
$32.00
Target median
$17.00
+72,1%
Target rata-rata
$20.82
+110,7%
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
Kejutan Rata-rata
0.02%
| Periode | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|
| 30 Juni 2026 | $0.30 | $0.12 | 0.18% |
| 31 Maret 2026 | $-0.09 | $0.05 | -0.14% |
| 31 Des. 2025 | $0.01 | $0.04 | -0.03% |
| 30 Sep. 2025 | $0.06 | $0.04 | 0.02% |
| 30 Juni 2025 | $0.04 | $0.01 | 0.03% |
| 31 Maret 2025 | $0.00 | $-0.07 | 0.07% |
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| BCRX | $1.66B | 6.4 | 94.1% | 30.2% | -97.6% | — |
| BEAM | $2.82B | -34.2 | 120.0% | -57.2% | -7.0% | — |
| KOD | $1.73B | -6.5 | — | — | -202.0% | — |
| SLS | $577M | -15.1 | — | — | -55.4% | — |
| RARE | $2.22B | -3.9 | 20.2% | -85.4% | -1613.2% | — |
| COAG | — | — | — | — | — | — |
| KLRA | — | — | — | — | — | — |
| CDNA | $959M | -47.1 | 13.8% | -5.6% | -6.8% | — |
| PGEN | $1.48B | -3.1 | 146.7% | -2588.2% | 3159.1% | — |
| VERA | — | -10.9 | — | — | -55.9% | — |
| MLYS | $2.96B | -15.8 | — | — | -32.2% | — |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi 16
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M | $48M | $14M | |
| Cost of Revenue | $19M | $12M | $4M | $6M | $7M | $2M | $4M | · | $1M | $2M | $1M | $1.0K | |
| R&D Expense | $166M | $175M | $217M | $253M | $209M | $123M | $107M | $85M | $67M | $61M | $73M | $52M | |
| SG&A Expense | $349M | $266M | $214M | $159M | $119M | $68M | $37M | $30M | $14M | $11M | $13M | $7M | |
| Operating Expenses | $534M | $453M | $435M | $419M | $335M | $193M | $148M | $115M | $83M | $75M | $88M | $59M | |
| Operating Income | $341M | $-3M | $-104M | $-148M | $-178M | $-175M | $-99M | $-94M | $-57M | $-49M | $-39M | $-46M | |
| Interest Expense | · | · | $108M | $99M | $59M | $15M | $12M | $9M | $9M | $6M | $5M | $5M | |
| Other Non-op | $-74M | $-84M | $-123M | $-96M | · | · | · | · | · | · | · | · | |
| Pretax Income | $267M | $-87M | $-226M | $-244M | $-182M | $-183M | $-109M | · | · | · | · | · | |
| Income Tax | $4M | $2M | $310.0K | $3M | $2M | $0 | $0 | $0 | $0 | $0 | $0 | · | |
| Net Income | $264M | $-89M | $-227M | $-247M | $-184M | $-183M | $-109M | $-101M | $-66M | $-55M | $-43M | $-45M | |
| EPS (Basic) | $1.26 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | · | · | · | · | · | · | |
| EPS (Diluted) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | · | · | · | · | · | · | |
| Shares (Basic) | 209,893,000 | 206,696,000 | 192,198,000 | 185,908,000 | 179,117,000 | 167,267,000 | · | · | · | · | · | · | |
| Shares (Diluted) | 218,581,000 | 206,696,000 | 192,198,000 | 185,908,000 | 179,117,000 | 167,267,000 | 115,600,000 | 103,185,000 | 84,451,000 | 73,699,000 | 72,901,000 | 66,773,000 | |
| EBITDA | $342M | $-1M | $-102M | $-147M | $-177M | $-174M | $-99M | $-93M | · | $-48M | $-39M | $-46M |
Neraca 27
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $90M | $105M | $111M | $305M | $504M | $272M | $114M | $27M | $50M | $22M | $29M | $55M | |
| Short-term Investments | $185M | $216M | · | · | · | · | · | · | · | · | · | · | |
| Receivables | $107M | $79M | $57M | $51M | $29M | $9M | $22M | $4M | $6M | $9M | $6M | $4M | |
| Inventory | $5M | $8M | $29M | $28M | $16M | $7M | $0 | $2M | · | $500.0K | $2M | $683.0K | |
| Prepaid Expense | $17M | $14M | $20M | $13M | $10M | $6M | $4M | $2M | $1M | $1M | $3M | $6M | |
| Current Assets | $404M | $422M | $496M | $516M | $566M | $324M | $164M | $114M | $125M | $67M | $64M | $89M | |
| PP&E (Net) | $9M | $8M | $8M | $9M | $9M | $7M | $7M | $9M | $10M | $10M | $5M | $207.0K | |
| PP&E (Gross) | $18M | $20M | $19M | $18M | $17M | $14M | $14M | $15M | $15M | $15M | $19M | $14M | |
| Accum. Depreciation | $9M | $12M | $11M | $10M | $8M | $7M | $7M | $6M | $5M | $5M | $14M | $14M | |
| Other Non-current Assets | $6M | $5M | $80.0K | $7M | $6M | $4M | $4M | $978.0K | $2M | $4M | $5M | $6M | |
| Total Assets | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M | $122M | $137M | |
| Accounts Payable | $16M | $12M | $21M | $14M | $28M | $19M | $14M | $8M | $6M | $4M | $9M | $3M | |
| Accrued Liabilities | $126M | $113M | $103M | $88M | $73M | $34M | $21M | $16M | $13M | $11M | $16M | $11M | |
| Short-term Debt | · | · | · | · | · | $30M | $30M | $29M | $29M | $28M | $28M | $30M | |
| Current Liabilities | $196M | $160M | $150M | $106M | $104M | $106M | $92M | $69M | $75M | $54M | $62M | $57M | |
| Capital Leases | $9M | $8M | $8M | $4M | $6M | $4M | · | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | $3M | · | · | · | · | |
| Total Liabilities | $633M | $966M | $972M | · | · | · | · | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | $298M | $123M | $50M | $30M | $23M | $23M | · | · | |
| Total Debt | $0 | $315M | $303M | $232M | $136M | $150M | $30M | $29M | · | $28M | $30M | $30M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $984.0K | $738.0K | $734.0K | $720.0K | |
| Paid-in Capital | $1.38B | $1.29B | $1.22B | $1.16B | $1.10B | $1.00B | $877M | $780M | $715M | $567M | $558M | $543M | |
| Retained Earnings | $-1.51B | $-1.77B | $-1.68B | $-1.45B | $-1.21B | $-1.02B | $-841M | $-732M | $-632M | $-566M | $-511M | $-468M | |
| AOCI | $38.0K | $921.0K | $1M | $26.0K | $177.0K | $3.0K | $39.0K | $-297.0K | $-243.0K | $-12.0K | $-206.0K | $-130.0K | |
| Stockholders' Equity | $-119M | $-476M | $-456M | $-295M | $-107M | $-19M | $38M | $49M | $84M | $2M | $48M | $76M | |
| Liabilities + Equity | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M | $122M | $137M | |
| Shares Outstanding | 213,060,000 | 208,543,000 | 205,771,000 | 187,906,000 | 184,350,000 | 176,883,000 | 154,082,000 | 110,063,000 | 98,411,000 | 73,782,000 | 73,355,000 | 71,955,000 |
Arus Kas 16
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $2M | $1M | $777.0K | $748.0K | $724.0K | $770.0K | $704.0K | $483.0K | $180.0K | $177.0K | |
| Stock-based Comp | $85M | $65M | $56M | $45M | $35M | $15M | $18M | $9M | $13M | $8M | $10M | $10M | |
| Deferred Tax | $-1M | $-354.0K | $-682.0K | $11.0K | $-159.0K | · | · | · | · | · | · | · | |
| Other Non-cash | $-2M | $-29M | $75M | $39M | $6M | $30M | $870.0K | $-1M | · | $-7M | $20M | $-4M | |
| Operating Cash Flow | $347M | $-52M | $-95M | $-162M | $-142M | $-135M | $-90M | $-93M | $-41M | $-53M | $-13M | $-39M | |
| CapEx | $2M | $1M | $2M | $1M | $2M | $514.0K | $343.0K | $366.0K | $328.0K | $5M | $5M | $106.0K | |
| Investing Cash Flow | $-14M | $53M | $-131M | $-128M | $16M | $-7M | $78M | $5M | $-65M | $23M | $-18M | · | |
| Debt Issued | $0 | $0 | $300M | $73M | $0 | · | · | · | · | · | · | · | |
| Net Debt Issued | $-300M | $0 | $300M | · | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $0 | $0 | $50M | $93M | $58M | $53M | $134M | · | · | $107M | |
| Net Stock Activity | · | · | $0 | $0 | $50M | $93M | $58M | $53M | · | · | · | $107M | |
| Financing Cash Flow | $-350M | $-6M | $32M | $88M | $360M | $301M | $99M | $63M | $136M | $23M | $5M | · | |
| Net Change in Cash | $-15M | $-6M | $-194M | $-201M | $233M | $159M | $87M | $-25M | $30M | $-7M | $-26M | $33M | |
| Taxes Paid | $3M | $2M | $1M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $345M | $-53M | $-97M | $-163M | $-145M | $-138M | $-90M | $-93M | · | $-59M | $-18M | $-39M | |
| Levered FCF | · | · | $-206M | $-263M | $-205M | $-152M | · | · | · | · | · | · |
Profitabilitas 7
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 39.0% | -0.56% | -31.3% | -54.8% | -113.1% | -981.1% | -203.7% | -456.2% | · | -184.4% | -81.7% | -336.4% | |
| Net Margin | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% | -1026.4% | -223.0% | -490.2% | · | -209.2% | -89.1% | -332.1% | |
| Pretax Margin | 30.6% | -19.3% | -68.3% | -90.2% | -115.7% | -1026.4% | · | · | · | · | · | · | |
| EBITDA Margin | 39.1% | -0.29% | -30.8% | -54.3% | -112.6% | -976.9% | -202.2% | -452.5% | · | -182.6% | -81.4% | -335.0% | |
| ROA | 52.5% | -17.6% | -42.5% | -43.4% | -39.9% | -71.7% | -67.6% | -62.3% | · | -52.0% | -32.9% | -48.7% | |
| ROE | -97.6% | 18.8% | 52.3% | 92.0% | 144.9% | -2543.5% | 7257.4% | -165.8% | · | -223.7% | -69.8% | -121.3% | |
| ROIC | -282.4% | 1.6% | 68.2% | 238.4% | -618.4% | -133.9% | · | · | · | · | · | · |
Likuiditas & Solvabilitas 5
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.1 | 2.6 | 3.3 | 4.9 | 5.5 | 3.1 | 1.8 | 1.6 | · | 1.2 | 1.0 | 1.5 | |
| Quick Ratio | 1.9 | 1.1 | 1.1 | 3.4 | 5.1 | 2.7 | 1.5 | 0.4 | · | 0.6 | 0.5 | 0.9 | |
| Debt / Equity | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 | -7.8 | 0.8 | 0.6 | · | 17.9 | 0.6 | 0.4 | |
| LT Debt / Equity | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 | -6.2 | · | · | · | · | · | · | |
| Interest Coverage | · | · | -1.0 | -1.5 | -3.0 | -12.1 | -8.4 | -10.3 | · | -7.5 | -7.6 | -9.2 |
Efisiensi 3
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.7 | 0.9 | 0.6 | 0.5 | 0.3 | 0.1 | 0.3 | 0.1 | · | 0.2 | 0.4 | 0.1 | |
| Inventory Turnover | 2.8 | 0.4 | 0.2 | 0.3 | 0.6 | 0.4 | · | · | · | 2.2 | 1.2 | 0.0 | |
| Receivables Turnover | 9.4 | 6.6 | 6.2 | 6.8 | 8.3 | 1.2 | 3.7 | 4.0 | · | 3.5 | 9.6 | · |
Tingkat Pertumbuhan 3
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 94.1% | 36.0% | 22.4% | 72.3% | 782.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 47.8% | 42.1% | 165.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 117.9% | · | · | · | · | · | · | · | · | · | · | · |
Valuasi (TTM) 13
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M | $48M | $14M | |
| Net Income TTM | $264M | $-89M | $-227M | $-247M | $-184M | $-183M | $-109M | $-101M | $-66M | $-55M | $-43M | $-45M | |
| Market Cap | $1.66B | $1.57B | $1.23B | $2.16B | $2.55B | $1.32B | $532M | $888M | · | $467M | $757M | $875M | |
| Enterprise Value | $1.39B | $1.78B | $1.43B | $2.08B | $2.18B | $1.20B | $447M | $891M | · | $473M | $758M | $850M | |
| P/E | 6.4 | -17.5 | -5.1 | -8.6 | -13.4 | -6.8 | -5.7 | -13.2 | -8.0 | -10.4 | -17.2 | · | |
| P/S | 1.9 | 3.5 | 3.7 | 8.0 | 16.2 | 74.0 | 10.9 | 43.0 | · | 17.7 | 15.7 | 64.3 | |
| P/B | -13.9 | -3.3 | -2.7 | -7.3 | -23.9 | -68.4 | 13.9 | 18.0 | · | 296.0 | 15.9 | 11.6 | |
| P / Cash Flow | 4.8 | -30.1 | -13.0 | -13.3 | -18.0 | -9.6 | -5.9 | -9.6 | · | -8.7 | -57.7 | -22.7 | |
| P / FCF | 4.8 | -29.5 | -12.7 | -13.2 | -17.7 | -9.6 | -5.9 | -9.6 | · | -8.0 | -41.5 | -22.6 | |
| EV / EBITDA | 4.1 | -1371.2 | -14.0 | -14.2 | -12.3 | -6.9 | -4.5 | -9.5 | · | -9.8 | -19.3 | -18.7 | |
| EV / FCF | 4.0 | -33.5 | -14.6 | -12.8 | -15.1 | -8.7 | -5.0 | -9.6 | · | -8.1 | -41.6 | -22.0 | |
| EV / Revenue | 1.6 | 3.9 | 4.3 | 7.7 | 13.9 | 67.1 | 9.2 | 43.1 | · | 18.0 | 15.7 | 62.5 | |
| Earnings Yield | 15.5% | -5.7% | -19.7% | -11.6% | -7.4% | -14.6% | -17.7% | -7.6% | -12.4% | -9.6% | -5.8% | · |
Laporan Laba Rugi 16
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $218M | $156M | $407M | $159M | $163M | $146M | $132M | $117M | $109M | $93M | $93M | $87M | $82M | $69M | $80M | $76M | |
| Cost of Revenue | $4M | $5M | $10M | $2M | $3M | $5M | $6M | $3M | $2M | $1M | $2M | $1M | $894.0K | $931.0K | $2M | $4M | |
| R&D Expense | $52M | $60M | $41M | $45M | $43M | $37M | $49M | $41M | $38M | $46M | $70M | $47M | $51M | $48M | $73M | $53M | |
| SG&A Expense | $64M | $95M | $96M | $83M | $87M | $82M | $81M | $65M | $61M | $59M | $65M | $51M | $51M | $48M | $50M | $37M | |
| Operating Expenses | $120M | $858M | $146M | $130M | $134M | $124M | $136M | $109M | $101M | $107M | $136M | $99M | $103M | $97M | $126M | $93M | |
| Operating Income | $98M | $-702M | $260M | $30M | $30M | $21M | $-5M | $8M | $9M | $-14M | $-43M | $-12M | $-21M | $-28M | $-46M | $-17M | |
| Interest Expense | · | · | · | · | · | · | · | · | $25M | $25M | · | $27M | $29M | $27M | · | $25M | |
| Other Non-op | $260.0K | $-1M | $-12M | $-17M | $0 | $0 | $-21M | $-21M | $-21M | $-21M | · | · | · | · | · | · | |
| Pretax Income | $79M | $-721M | $248M | $12M | $6M | $758.0K | $-26M | $-13M | $-13M | $-35M | $-63M | $-36M | $-75M | $-53M | $-71M | $-41M | |
| Income Tax | $1M | $1M | $2M | $-769.0K | $1M | $726.0K | $804.0K | $586.0K | $172.0K | $365.0K | $-1M | $330.0K | $740.0K | $671.0K | $76.0K | $2M | |
| Net Income | $78M | $-722M | $246M | $13M | $5M | $32.0K | $-27M | $-14M | $-13M | $-35M | $-62M | $-36M | $-75M | $-53M | $-72M | $-43M | |
| EPS (Basic) | $0.31 | $-2.98 | $1.18 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | |
| EPS (Diluted) | $0.30 | $-2.98 | $1.13 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | |
| Shares (Basic) | 254,481,000 | 242,258,000 | -418,684,000 | 210,176,000 | 209,519,000 | 208,882,000 | -412,698,000 | 206,905,000 | 206,425,000 | 206,064,000 | -375,073,000 | 189,644,000 | 189,118,000 | 188,509,000 | -370,775,000 | 186,180,000 | |
| Shares (Diluted) | 265,165,000 | 242,258,000 | -436,451,000 | 219,885,000 | 219,886,000 | 215,261,000 | -412,698,000 | 206,905,000 | 206,425,000 | 206,064,000 | -375,073,000 | 189,644,000 | 189,118,000 | 188,509,000 | -370,775,000 | 186,180,000 | |
| EBITDA | $98M | $-702M | · | $30M | $30M | $22M | · | $8M | $9M | $-14M | · | $-12M | $-21M | $-28M | · | $-17M |
Neraca 24
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $155M | $172M | $90M | $84M | $88M | $105M | $105M | $97M | $78M | $84M | $111M | $151M | $146M | $155M | $305M | $247M | |
| Short-term Investments | $198M | $67M | $185M | $129M | $172M | $190M | $216M | · | · | · | · | · | · | · | · | · | |
| Receivables | $111M | $109M | $107M | $91M | $91M | $93M | $79M | $72M | $69M | $61M | · | $54M | $58M | $49M | · | $43M | |
| Inventory | $6M | $6M | $5M | $5M | $5M | $7M | $8M | $8M | $4M | $30M | · | $30M | $27M | $27M | · | $27M | |
| Prepaid Expense | $15M | $19M | $17M | $17M | $13M | $14M | $14M | $16M | $16M | $18M | · | $20M | $14M | $15M | · | $11M | |
| Current Assets | $485M | $374M | $404M | $356M | $398M | $410M | $422M | $427M | $363M | $447M | · | $502M | $511M | $491M | · | $509M | |
| PP&E (Net) | $9M | $9M | $9M | $8M | $8M | $8M | $8M | $7M | $8M | $8M | · | $9M | $8M | $8M | · | $8M | |
| PP&E (Gross) | · | · | $18M | · | · | · | $20M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $9M | · | · | · | $12M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $20M | $20M | $6M | $4M | $4M | $5M | $5M | $16M | $12M | $13M | · | $11M | $7M | $7M | · | $7M | |
| Total Assets | $558M | $465M | $514M | $446M | $457M | $480M | $490M | $491M | $472M | $468M | · | $523M | $530M | $510M | · | $559M | |
| Accounts Payable | $11M | $11M | $16M | $6M | $9M | $10M | $12M | $13M | $8M | $12M | · | $11M | $14M | $6M | · | $9M | |
| Accrued Liabilities | $122M | $119M | $126M | $119M | $107M | $93M | $113M | $104M | $90M | $79M | · | $77M | $75M | $75M | · | $69M | |
| Current Liabilities | $209M | $195M | $196M | $190M | $177M | $140M | $160M | $154M | $129M | $120M | · | $91M | $93M | $85M | · | $82M | |
| Capital Leases | $11M | $11M | $9M | $8M | $8M | $8M | $8M | $8M | $8M | $9M | · | $10M | $6M | $6M | · | $6M | |
| Total Liabilities | $1.01B | $1.02B | $633M | $834M | $879M | $932M | $966M | $960M | · | · | · | · | · | · | · | · | |
| Total Debt | $395M | $395M | · | $194M | $243M | $315M | · | $314M | $314M | $308M | · | $298M | $293M | $233M | · | $224M | |
| Common Stock | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Paid-in Capital | $1.69B | $1.67B | $1.38B | $1.36B | $1.34B | $1.31B | $1.29B | $1.27B | $1.25B | $1.24B | · | $1.21B | $1.19B | $1.18B | · | $1.14B | |
| Retained Earnings | $-2.15B | $-2.23B | $-1.51B | $-1.75B | $-1.76B | $-1.77B | $-1.77B | $-1.74B | $-1.73B | $-1.72B | · | $-1.62B | $-1.58B | $-1.51B | · | $-1.38B | |
| AOCI | $-528.0K | $-368.0K | $38.0K | $1M | $2M | $1M | $921.0K | $2M | $557.0K | $771.0K | · | $800.0K | $690.0K | $585.0K | · | $-98.0K | |
| Stockholders' Equity | $-454M | $-554M | $-119M | $-388M | $-422M | $-452M | $-476M | $-469M | $-476M | $-476M | $-456M | $-411M | $-389M | $-328M | $-295M | $-243M | |
| Liabilities + Equity | $558M | $465M | $514M | $446M | $457M | $480M | $490M | $491M | $472M | $468M | · | $523M | $530M | $510M | · | $559M | |
| Shares Outstanding | 255,265,000 | 254,014,000 | 213,060,000 | 210,522,000 | 209,905,000 | 209,208,000 | 208,543,000 | 207,119,000 | 206,629,000 | 206,347,000 | 205,771,000 | 189,803,000 | 189,491,000 | 188,883,000 | 187,906,000 | 186,411,000 |
Arus Kas 14
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | $394.0K | $335.0K | $329.0K | $331.0K | $309.0K | $311.0K | $320.0K | $306.0K | $423.0K | $420.0K | $407.0K | $405.0K | $396.0K | $389.0K | |
| Stock-based Comp | $15M | $16M | $24M | $19M | $21M | $21M | $21M | $17M | $13M | $14M | $16M | $12M | $13M | $14M | $15M | $10M | |
| Amort. of Intangibles | $0 | $600.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | $-49M | · | · | · | $-32M | · | · | · | $-9M | · | · | |
| Operating Cash Flow | $104M | $-62M | $292M | $42M | $41M | $-28M | $-5M | $8M | $-1M | $-54M | $-9M | $-20M | $-19M | $-48M | $-24M | $-32M | |
| CapEx | $209.0K | $403.0K | $802.0K | $1M | $179.0K | $143.0K | $675.0K | $59.0K | $155.0K | $235.0K | $554.0K | $987.0K | $467.0K | $160.0K | $526.0K | $175.0K | |
| Investing Cash Flow | $-110M | $-269M | $-83M | $14M | $29M | $27M | $18M | $8M | $-2M | $29M | $-28M | $23M | $-19M | $-107M | $77M | $-70M | |
| Debt Issued | $0 | $400M | · | · | $0 | $0 | $0 | $0 | · | · | $0 | $0 | · | · | $0 | $73M | |
| Net Debt Issued | · | $400M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-11M | $413M | $-218M | $-59M | $-74M | $529.0K | $-4M | $1M | $-2M | $-1M | $-3M | $1M | $29M | $5M | $4M | $76M | |
| Net Change in Cash | $-17M | $82M | · | · | $-17M | $558.0K | $7M | $19M | $-6M | $-26M | $-40M | $5M | $-9M | $-150M | $58M | $-26M | |
| Taxes Paid | $2M | $1M | · | · | $1M | $1.0K | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $-62M | · | · | · | $-28M | · | · | · | $-54M | · | · | · | $-48M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-79M | · | · | · | $-75M | · | · |
Profitabilitas 7
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 45.1% | -448.6% | · | 18.6% | 18.2% | 14.6% | · | 6.6% | 8.0% | -15.6% | · | -13.7% | -25.1% | -41.3% | · | -23.0% | |
| Net Margin | 35.9% | -461.5% | · | 8.1% | 3.1% | 0.02% | · | -12.0% | -11.6% | -38.1% | · | -41.7% | -91.3% | -77.5% | · | -56.1% | |
| Pretax Margin | 36.4% | -460.8% | · | 7.6% | 4.0% | 0.52% | · | -11.5% | -11.4% | -37.8% | · | -41.3% | -90.4% | -76.6% | · | -54.1% | |
| EBITDA Margin | 45.1% | -448.6% | · | 18.6% | 18.2% | 14.8% | · | 6.6% | 8.0% | -15.3% | · | -13.7% | -25.1% | -40.7% | · | -23.0% | |
| ROA | 15.4% | -152.8% | · | 2.8% | 1.1% | 0.01% | · | -2.8% | -2.5% | -7.2% | · | -6.7% | -14.5% | -10.3% | · | -10.3% | |
| ROE | -17.9% | 143.5% | · | -3.0% | -1.1% | -0.01% | · | 3.2% | 2.9% | 8.8% | · | 11.1% | 25.0% | 21.7% | · | 21.8% | |
| ROIC | -164.9% | 442.9% | · | -16.3% | -13.1% | -0.66% | · | -5.2% | -5.5% | 8.7% | · | 10.7% | 21.9% | 30.0% | · | 96.3% |
Likuiditas & Solvabilitas 5
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 1.9 | · | 1.9 | 2.2 | 2.9 | · | 2.8 | 2.8 | 3.7 | · | 5.5 | 5.5 | 5.8 | · | 6.2 | |
| Quick Ratio | 2.2 | 1.8 | · | 1.6 | 2.0 | 2.8 | · | 1.1 | 1.1 | 1.2 | · | 2.3 | 2.2 | 2.4 | · | 3.5 | |
| Debt / Equity | -0.9 | -0.7 | · | -0.5 | -0.6 | -0.7 | · | -0.7 | -0.7 | -0.6 | · | -0.7 | -0.8 | -0.7 | · | -0.9 | |
| LT Debt / Equity | -0.9 | -0.7 | · | -0.5 | -0.6 | -0.7 | · | -0.7 | -0.7 | -0.6 | · | -0.7 | -0.8 | -0.7 | · | -0.9 | |
| Interest Coverage | · | · | · | · | · | · | · | · | 0.4 | -0.6 | · | -0.4 | -0.7 | -1.0 | · | -0.7 |
Efisiensi 3
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.3 | · | 0.3 | 0.4 | 0.3 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | |
| Inventory Turnover | 0.7 | 0.8 | · | 0.3 | 0.6 | 0.2 | · | 0.2 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.2 | |
| Receivables Turnover | 2.2 | 1.5 | · | 1.9 | 2.0 | 1.9 | · | 1.9 | 1.7 | 1.7 | · | 1.8 | 1.7 | 1.6 | · | 2.2 |
Valuasi (TTM) 13
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $697M | $625M | · | $585M | $535M | $465M | · | $406M | $371M | $331M | · | $314M | $293M | $260M | · | $232M | |
| Net Income TTM | $-625M | $-704M | · | $4M | $-22M | $-62M | · | $-98M | $-160M | $-200M | · | $-207M | $-230M | $-229M | · | $-234M | |
| Market Cap | $2.55B | $2.42B | · | $1.60B | $1.88B | $1.57B | · | $1.57B | $1.28B | $1.05B | · | $1.34B | $1.33B | $1.58B | · | $2.35B | |
| Enterprise Value | $2.60B | $2.58B | · | $1.58B | $1.86B | $1.59B | · | $1.79B | $1.51B | $1.27B | · | $1.49B | $1.48B | $1.65B | · | $2.33B | |
| P/E | -3.8 | -3.3 | · | 759.0 | -81.5 | -25.0 | · | -15.5 | -7.5 | -4.9 | · | -6.4 | -5.7 | -6.8 | · | -9.8 | |
| P/S | 3.7 | 3.9 | · | 2.7 | 3.5 | 3.4 | · | 3.9 | 3.4 | 3.2 | · | 4.3 | 4.6 | 6.1 | · | 10.1 | |
| P/B | -5.6 | -4.4 | · | -4.1 | -4.5 | -3.5 | · | -3.4 | -2.7 | -2.2 | · | -3.3 | -3.4 | -4.8 | · | -9.7 | |
| P / Cash Flow | · | -39.1 | · | · | · | -57.0 | · | · | · | -19.5 | · | · | · | -33.2 | · | · | |
| P / FCF | · | -38.9 | · | · | · | -56.7 | · | · | · | -19.4 | · | · | · | -33.0 | · | · | |
| EV / EBITDA | 26.4 | -3.7 | · | 53.4 | 62.6 | 73.7 | · | 232.9 | 172.6 | -89.7 | · | -125.1 | -71.5 | -59.0 | · | -133.3 | |
| EV / FCF | · | -41.4 | · | · | · | -57.5 | · | · | · | -23.6 | · | · | · | -34.7 | · | · | |
| EV / Revenue | 3.7 | 4.1 | · | 2.7 | 3.5 | 3.4 | · | 4.4 | 4.1 | 3.8 | · | 4.8 | 5.1 | 6.4 | · | 10.0 | |
| Earnings Yield | -26.0% | -30.5% | · | 0.13% | -1.2% | -4.0% | · | -6.5% | -13.3% | -20.5% | · | -15.5% | -17.5% | -14.8% | · | -10.2% |
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
Laporan Laba Rugi
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Pendapatan | $875M | $451M | $331M | $271M | $157M |
| Margin Operasi % | 39.0% | -0.56% | -31.3% | -54.8% | -113.1% |
| Laba Bersih | $264M | $-89M | $-227M | $-247M | $-184M |
| EPS Dilusian | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 |
Neraca
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Utang / Ekuitas | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 |
| Rasio Lancar | 2.1 | 2.6 | 3.3 | 4.9 | 5.5 |
| Rasio Cepat | 1.9 | 1.1 | 1.1 | 3.4 | 5.1 |
Arus Kas
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Arus Kas Bebas | $345M | $-53M | $-97M | $-163M | $-145M |
Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
📊
Pilih metrik yang penting bagi Anda — klik ➕ di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Pemilik institusional (13F) 346 pengaju · $2.1B total · Per tanggal 30 Juni 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 63 (-7 vs Kuartal sebelumnya) | 34 (-7 vs Kuartal sebelumnya) | 130 (+19 vs Kuartal sebelumnya) | 83 (+3 vs Kuartal sebelumnya) | +25.9M |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $158.271.860 | 15.827.186 | 7,51% | Saham |
| STATE STREET CORP | $151.910.980 | 15.191.098 | 7,21% | Saham |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $150.964.030 | 15.096.403 | 7,16% | Saham |
| VANGUARD CAPITAL MANAGEMENT LLC | $113.642.360 | 11.364.236 | 5,39% | Saham |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $111.391.580 | 11.139.158 | 5,29% | Saham |
| TCG Crossover Management, LLC | $110.209.680 | 11.020.968 | 5,23% | Saham |
| PERCEPTIVE ADVISORS LLC | $103.088.880 | 10.308.888 | 4,89% | Saham |
| JANUS HENDERSON GROUP PLC | $83.961.589 | 8.814.865 | 3,98% | Saham |
| Vestal Point Capital, LP | $83.000.000 | 8.300.000 | 3,94% | Saham |
| TWO SIGMA INVESTMENTS, LP | $67.753.490 | 6.775.349 | 3,21% | Saham |
| GEODE CAPITAL MANAGEMENT, LLC | $53.581.572 | 5.356.880 | 2,54% | Saham |
| Aberdeen Group plc | $53.108.710 | 5.310.871 | 2,52% | Saham |
| Frazier Life Sciences Management, L.P. | $40.092.400 | 4.009.240 | 1,90% | Saham |
| GOLDMAN SACHS GROUP INC | $35.393.210 | 3.539.321 | 1,68% | Saham |
| MILLENNIUM MANAGEMENT LLC | $33.947.290 | 3.394.729 | 1,61% | Saham |
| TWO SIGMA ADVISERS, LP | $31.895.074 | 4.089.112 | 1,51% | Saham |
| RP Management, LLC | $28.846.155 | 3.846.154 | 1,37% | Saham |
| DIMENSIONAL FUND ADVISORS LP | $27.161.110 | 2.716.111 | 1,29% | Saham |
| Fisher Asset Management, LLC | $26.040.270 | 2.604.027 | 1,24% | Saham |
| RENAISSANCE TECHNOLOGIES LLC | $25.302.900 | 2.530.290 | 1,20% | Saham |
| Kynam Capital Management, LP | $25.226.600 | 2.522.660 | 1,20% | Saham |
| Candriam S.C.A. | $25.125.293 | 2.514.949 | 1,19% | Saham |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $23.532.910 | 2.353.291 | 1,12% | Saham |
| RICE HALL JAMES & ASSOCIATES, LLC | $23.320.430 | 2.332.043 | 1,11% | Saham |
| AQR CAPITAL MANAGEMENT LLC | $21.850.110 | 2.185.011 | 1,04% | Saham |
| Nantahala Capital Management, LLC | $19.011.600 | 1.901.160 | 0,90% | Saham |
| Eversept Partners, LP | $18.656.530 | 1.865.653 | 0,89% | Saham |
| ORBIMED ADVISORS LLC | $18.520.000 | 1.852.000 | 0,88% | Saham |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $18.449.120 | 1.844.912 | 0,88% | Saham |
| VANGUARD FIDUCIARY TRUST CO | $17.595.730 | 1.759.573 | 0,83% | Saham |
| CITADEL ADVISORS LLC | $17.591.600 | 1.759.160 | 0,83% | Saham |
| IMC-Chicago, LLC | $16.343.360 | 1.634.336 | 0,78% | Saham |
| Parkman Healthcare Partners LLC | $16.242.790 | 1.624.279 | 0,77% | Saham |
| JANE STREET GROUP, LLC | $14.267.680 | 1.426.768 | 0,68% | Saham |
| OP Asset Management Ltd | $13.409.900 | 1.340.990 | 0,64% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $11.956.510 | 1.195.651 | 0,57% | Saham |
| Pictet Asset Management Holding SA | $11.951.392 | 1.249.771 | 0,57% | Saham |
| BNP PARIBAS FINANCIAL MARKETS | $11.740.520 | 1.174.052 | 0,56% | Saham |
| FIRST TRUST ADVISORS LP | $11.204.690 | 1.120.469 | 0,53% | Saham |
| JANE STREET GROUP, LLC | $9.944.130 | 994.413 | 0,47% | Opsi beli |
| Cubist Systematic Strategies, LLC | $9.462.419 | 1.246.696 | 0,45% | Saham |
| MOORE CAPITAL MANAGEMENT, LP | $8.483.360 | 848.336 | 0,40% | Saham |
| FMR LLC | $8.062.330 | 806.233 | 0,38% | Saham |
| BANK OF AMERICA CORP /DE/ | $7.754.020 | 775.402 | 0,37% | Saham |
| ExodusPoint Capital Management, LP | $7.449.170 | 744.917 | 0,35% | Saham |
| Man Group plc | $7.324.800 | 732.480 | 0,35% | Saham |
| Rosalind Advisors, Inc. | $7.215.040 | 721.504 | 0,34% | Saham |
| Schonfeld Strategic Advisors LLC | $7.108.160 | 710.816 | 0,34% | Saham |
| BlackRock, Inc. | $5.984.400 | 598.440 | 0,28% | Saham |
| Elmind Capital, LP | $5.200.000 | 520.000 | 0,25% | Saham |
| Bridgewater Associates, LP | $4.910.570 | 491.057 | 0,23% | Saham |
| NAN FUNG TRINITY (HK) LTD | $4.500.000 | 450.000 | 0,21% | Saham |
| SPHERA FUNDS MANAGEMENT LTD. | $4.220.510 | 422.051 | 0,20% | Saham |
| Swiss National Bank | $4.152.680 | 415.268 | 0,20% | Saham |
| Susquehanna Portfolio Strategies, LLC | $4.047.040 | 404.704 | 0,19% | Saham |
| DAFNA Capital Management LLC | $4.002.480 | 400.248 | 0,19% | Saham |
| Hudson Bay Capital Management LP | $4.000.000 | 400.000 | 0,19% | Saham |
| Aquatic Capital Management LLC | $3.628.950 | 362.895 | 0,17% | Saham |
| DOLIVER CAPITAL ADVISORS, INC. | $3.563.603 | 374.328 | 0,17% | Saham |
| Assenagon Asset Management S.A. | $3.530.440 | 353.044 | 0,17% | Saham |
| Kodai Capital Management LP | $3.515.993 | 468.799 | 0,17% | Saham |
| MACKENZIE FINANCIAL CORP | $3.472.990 | 347.299 | 0,16% | Saham |
| CITIGROUP INC | $3.467.520 | 346.752 | 0,16% | Saham |
| Phocas Financial Corp. | $3.405.410 | 340.541 | 0,16% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $3.238.000 | 323.800 | 0,15% | Opsi beli |
| ALPS ADVISORS INC | $3.179.600 | 317.960 | 0,15% | Saham |
| ALLIANCEBERNSTEIN L.P. | $3.121.694 | 327.909 | 0,15% | Saham |
| RHUMBLINE ADVISERS | $2.798.390 | 279.839 | 0,13% | Saham |
| Rafferty Asset Management, LLC | $2.656.180 | 265.618 | 0,13% | Saham |
| Point72 Asset Management, L.P. | $2.609.170 | 260.917 | 0,12% | Saham |
| Nuveen, LLC | $2.599.030 | 259.903 | 0,12% | Saham |
| NFJ INVESTMENT GROUP, LLC | $2.568.330 | 256.833 | 0,12% | Saham |
| Nebula Research & Development LLC | $2.567.121 | 286.509 | 0,12% | Saham |
| WINTON GROUP Ltd | $2.556.000 | 255.600 | 0,12% | Saham |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $2.459.444 | 258.345 | 0,12% | Saham |
| MARTINGALE ASSET MANAGEMENT L P | $2.425.080 | 242.508 | 0,12% | Saham |
| WELLINGTON MANAGEMENT GROUP LLP | $2.324.670 | 232.467 | 0,11% | Saham |
| CITADEL ADVISORS LLC | $2.322.000 | 232.200 | 0,11% | Opsi beli |
| IEQ CAPITAL, LLC | $2.274.210 | 227.421 | 0,11% | Saham |
| Bank of New York Mellon Corp | $2.251.670 | 225.167 | 0,11% | Saham |
| D. E. Shaw & Co., Inc. | $2.249.120 | 224.912 | 0,11% | Saham |
| JUPITER ASSET MANAGEMENT LTD | $2.221.030 | 222.103 | 0,11% | Saham |
| HUSSMAN STRATEGIC ADVISORS, INC. | $2.100.000 | 210.000 | 0,10% | Saham |
| PFM Health Sciences, LP | $2.073.570 | 207.357 | 0,10% | Saham |
| VANGUARD ASSET MANAGEMENT, Ltd | $1.962.800 | 196.280 | 0,09% | Saham |
| TUDOR INVESTMENT CORP ET AL | $1.951.280 | 195.128 | 0,09% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.853.000 | 185.300 | 0,09% | Opsi jual |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $1.820.161 | 233.354 | 0,09% | Saham |
| Engineers Gate Manager LP | $1.750.020 | 175.002 | 0,08% | Saham |
| Squarepoint Ops LLC | $1.747.140 | 174.714 | 0,08% | Saham |
| QTR Family Wealth, LLC | $1.610.820 | 161.082 | 0,08% | Saham |
| Gotham Asset Management, LLC | $1.564.210 | 156.421 | 0,07% | Saham |
| CITADEL ADVISORS LLC | $1.450.000 | 145.000 | 0,07% | Opsi jual |
| Corient Private Wealth LP | $1.429.860 | 142.986 | 0,07% | Saham |
| NEW YORK STATE COMMON RETIREMENT FUND | $1.386.570 | 138.657 | 0,07% | Saham |
| Quantinno Capital Management LP | $1.374.530 | 137.453 | 0,07% | Saham |
| MetLife Investment Management, LLC | $1.356.700 | 135.670 | 0,06% | Saham |
| PROFUND ADVISORS LLC | $1.340.340 | 134.034 | 0,06% | Saham |
| Virtus Investment Advisers, LLC | $1.336.640 | 133.664 | 0,06% | Saham |
| ADAR1 Capital Management, LLC | $1.330.000 | 133.000 | 0,06% | Saham |
Orang dalam perusahaan 51 orang dalam · 21 pejabat · 30 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Babar Ghias | Chief Financial Officer | 17 Des. 2025 A | 268.700 | 0 | 0 | $0 |
| Anthony Doyle | Chief Financial Officer | 19 Des. 2024 A | 377.867 | 0 | 0 | $0 |
| Thomas R Staab II | Senior Vice President and CFO | 21 Feb. 2020 A | 125.176 | 0 | 0 | $0 |
| Stuart Grant | SR VP & CFO | 16 Maret 2011 M | 57.102 | 0 | 0 | $0 |
| Charles K Gayer | President and CCO | 22 Des. 2025 M | 952.583 | 0 | 0 | $0 |
| Claude J Bennett | Chief Operating Officer | 14 Maret 2008 A | 65.730 | 0 | 0 | $0 |
| Alane P Barnes | Chief Legal Officer | 13 Mei 2026 M | 400.703 | 0 | 7 | $-3.461.969 |
| Sandeep Menon | Chief R&D Officer | 6 April 2026 A | 205.150 | 0 | 0 | $0 |
| Helen M. Thackray | Chief R&D Officer | 31 Maret 2025 F | 377.318 | 0 | 0 | $0 |
| Michael L Jones | Exec. Director, Finance - PAO | 19 Des. 2022 A | 16.653 | 0 | 0 | $0 |
| Yarlagadda S Babu | Chief Discovery Officer | 14 Nov. 2022 M | 298.541 | 0 | 0 | $0 |
| William P Sheridan | Chief Medical Officer | 10 Maret 2022 M | 37.954 | 0 | 0 | $0 |
| Megan Sniecinski | Chief Business Officer | 15 Des. 2020 A | 45.000 | 0 | 0 | $0 |
| Lynne Powell | Senior VP - CCO | 28 Jan. 2019 M | 0 | 0 | 0 | $0 |
| David Mccullough | VP | 15 Maret 2012 F | 24.124 | 0 | 0 | $0 |
| Robert S Lowrey | Controller, PAO | 7 Feb. 2011 A | 9.766 | 0 | 0 | $0 |
| Mike Mills | Principal Accounting Officer | 12 Maret 2010 M | 0 | 0 | 0 | $0 |
| Michael A Darwin | Principal Accounting Officer | 31 Juli 2008 P | 3.048 | 0 | 0 | $0 |
| Jonathan M Nugent | VP Corp Communications | 31 Juli 2007 P | 508 | 0 | 0 | $0 |
| James W Alexander | SR. VP, Chief Medical Officer | 31 Juli 2007 P | 3.659 | 0 | 0 | $0 |
| Randall B Riggs | Senior VP Business Development | 16 Mei 2007 A | 1.928 | 0 | 0 | $0 |
| Amy E Mckee | Direktur | 11 Juni 2026 A | 47.177 | 0 | 1 | $-100.285 |
| Theresa Heggie | Direktur | 11 Juni 2026 A | 80.646 | 0 | 1 | $-504.823 |
| Machelle Sanders | Direktur | 11 Juni 2026 A | 45.936 | 0 | 1 | $-68.544 |
| Jill C. Milne | Direktur | 11 Juni 2026 A | 31.938 | 0 | 0 | $0 |
| Steven Frank | Direktur | 11 Juni 2026 A | 35.459 | 0 | 0 | $0 |
| Steven K Galson | Direktur | 11 Juni 2026 A | 27.794 | 0 | 0 | $0 |
| Jon P Stonehouse | Direktur | 11 Juni 2026 A | 1.339.775 | 0 | 0 | $0 |
| Vincent Milano | Direktur | 11 Juni 2026 A | 108.483 | 0 | 0 | $0 |
| Alan G Levin | Direktur | 11 Juni 2026 A | 79.565 | 0 | 0 | $0 |
| Nancy J Hutson | Direktur | 12 Juni 2025 A | 99.138 | 0 | 0 | $0 |
| George B Abercrombie | Direktur | 12 Juni 2024 A | 36.431 | 0 | 0 | $0 |
| Steve Aselage | Direktur | 12 Juni 2024 A | 70.159 | 0 | 0 | $0 |
| Kenneth B Lee JR | Direktur | 13 Juni 2023 A | 68.863 | 0 | 0 | $0 |
| Robert Alexander Ingram | Direktur | 28 Feb. 2023 A | 100.198 | 0 | 0 | $0 |
| Stanley C Erck | Direktur | 28 Nov. 2018 M | 48.333 | 0 | 0 | $0 |
| Fred Cohen | Direktur | 20 Juni 2018 A | 119.410 | 0 | 0 | $0 |
| Sanj K Patel | Direktur | 24 Mei 2017 A | — | 0 | 0 | $0 |
| Charles A Sanders | Direktur | 29 Feb. 2016 A | 12.971 | 0 | 0 | $0 |
| Peder Jensen | Direktur | 2 Mei 2014 A | 60.000 | 0 | 0 | $0 |
| John L Higgins | Direktur | 23 Mei 2012 A | — | 0 | 0 | $0 |
| HOROVITZ ZOLA P | Direktur | 23 Mei 2012 A | 3.000 | 0 | 0 | $0 |
| Stephen R Biggar | Direktur | 12 Mei 2011 A | — | 0 | 0 | $0 |
| Beth C Seidenberg | Direktur | 13 Mei 2010 A | 3.000 | 0 | 0 | $0 |
| William W Featheringill | Direktur | 13 Mei 2010 A | 231.538 | 0 | 0 | $0 |
| William M Spencer III | Direktur | 16 Mei 2007 A | 186.761 | 0 | 0 | $0 |
| Joseph H Sherrill JR | Direktur | 16 Mei 2007 A | 451.900 | 0 | 0 | $0 |
| Charles E Bugg | Direktur | 18 Maret 2007 A | 62.439 | 0 | 0 | $0 |
| GORDON CARL L | Direktur | 17 Mei 2006 A | 1.100.000 | 0 | 0 | $0 |
| John A Montgomery | Direktur | 4 Nov. 2003 M | 46.785 | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Aktivis & pemilik 5%+ 15 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., Mr. David Kroin ×3 pengajuan | 31 Juli 2018 | — | Pengajuan awal | — | SEC |
| RA Capital Management, LLC, Peter Kolchinsky, RA Capital Healthcare Fund, L.P. | 2 April 2018 | — | Pengajuan awal | Investasi pasif | SEC |
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×5 pengajuan | 16 Agu 2016 | — | Pengajuan awal | — | SEC |
| Baker Bros. Advisors, LLC, Julian C. Baker, Felix J. Baker ×2 pengajuan | 23 Okt. 2012 | — | Pengajuan awal | — | SEC |
| Julian C. Baker, Felix J. Baker ×4 pengajuan | 13 Okt. 2011 | — | Pengajuan awal | — | SEC |
| L. John Doerr III, KPCB Pandemic and Bio Defense Fund, LLC, KPTV, LLC ×2 pengajuan | 20 Agu 2007 | — | Pengajuan awal | — | SEC |
| Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan | 7 Des. 2005 | — | Pengajuan awal | — | SEC |
| Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan | 7 Des. 2005 | — | Pengajuan awal | — | SEC |
| Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan | 7 Des. 2005 | — | Pengajuan awal | — | SEC |
| Orang pelapor yang tidak diungkapkan | 13 Okt. 2005 | — | Pengajuan awal | — | SEC |
| Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan | 26 Feb. 2004 | — | Pengajuan awal | — | SEC |
| Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan | 25 Feb. 2004 | — | Pengajuan awal | — | SEC |
| Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan | 24 Feb. 2004 | — | Pengajuan awal | — | SEC |
| Biotechnology Value Fund, L.P., Investment 10, L.L.C., Biotechnology Value Fund II, L.P., BVF Investments, L.L.C., BVF Partners L.P., BVF Inc. ×2 pengajuan | 31 Okt. 2003 | — | Pengajuan awal | — | SEC |
| William W. Featheringill | 14 Feb. 2002 | — | Pengajuan awal | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Kepemilikan ETF Dimiliki oleh 53 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 2,65% | 1.023.838 SH | 8 Agu 2026 | Harian |
| BBP · ETFis Series Trust I | 1,93% | 125.015 NS | 30 April 2026 | N-PORT |
| ABLS · Abacus FCF ETF Trust | 1,26% | 1.682 NS | 30 April 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,67% | 381.305 NS | 30 April 2026 | N-PORT |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,54% | 612.341 NS | 30 April 2026 | N-PORT |
| CALF · Pacer Funds Trust | 0,41% | 1.556.494 NS | 30 April 2026 | N-PORT |
| FYX · First Trust Exchange-Traded AlphaDE… | 0,28% | 364.624 NS | 30 April 2026 | N-PORT |
| BFOR · ALPS ETF Trust | 0,25% | 59.894 NS | 31 Mei 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,24% | 72.535 SH | 8 Agu 2026 | Harian |
| GSSC · Goldman Sachs ETF Trust | 0,19% | 213.133 NS | 31 Mei 2026 | N-PORT |
| SMLF · iShares Trust | 0,17% | 758.958 SH | 8 Agu 2026 | Harian |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,16% | 13.830 SH | 8 Agu 2026 | Harian |
| IBB · iShares Trust | 0,15% | 1.580.105 SH | 8 Agu 2026 | Harian |
| ESSC · Strategy Shares | 0,15% | 4.183 NS | 30 April 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,14% | 249.665 SH | 8 Agu 2026 | Harian |
| IWO · iShares Trust | 0,13% | 2.097.061 SH | 8 Agu 2026 | Harian |
| BIB · ProShares Trust | 0,11% | 9.271 NS | 31 Mei 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,11% | 57.134 NS | 30 April 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,10% | 81.871 NS | 30 April 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,07% | 1.339.774 SH | 8 Agu 2026 | Harian |
| ISCG · iShares Trust | 0,07% | 73.787 SH | 8 Agu 2026 | Harian |
| IWM · iShares Trust | 0,07% | 5.925.076 SH | 8 Agu 2026 | Harian |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,07% | 206.325 SH | 8 Agu 2026 | Harian |
| RSSL · Global X Funds | 0,06% | 97.958 NS | 30 April 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,05% | 806.097 NS | 30 April 2026 | N-PORT |
| ITWO · ProShares Trust | 0,05% | 10.652 NS | 31 Mei 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,05% | 1.154.262 NS | 31 Mei 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,04% | 1.696.014 SH | 8 Agu 2026 | Harian |
| ISCB · iShares Trust | 0,03% | 10.494 SH | 8 Agu 2026 | Harian |
| FHLC · FIDELITY COVINGTON TRUST | 0,03% | 96.151 NS | 30 April 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 2.837.341 SH | 8 Agu 2026 | Harian |
| VHT · VANGUARD WORLD FUND | 0,03% | 624.412 SH | 8 Agu 2026 | Harian |
| UWM · ProShares Trust | 0,03% | 8.331 NS | 31 Mei 2026 | N-PORT |
| URTY · ProShares Trust | 0,02% | 8.425 NS | 31 Mei 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,02% | 2.922.024 SH | 8 Agu 2026 | Harian |
| WSML · iShares Trust | 0,02% | 11.689 SH | 8 Agu 2026 | Harian |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,01% | 9.529 NS | 31 Mei 2026 | N-PORT |
| HDG · ProShares Trust | 0,01% | 212 NS | 31 Mei 2026 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0,01% | 80.493 NS | 31 Mei 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 74.317 NS | 30 April 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 72.218 SH | 8 Agu 2026 | Harian |
| AVUQ · AMERICAN CENTURY ETF TRUST | 0,00% | 937 NS | 31 Mei 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 336.352 SH | 8 Agu 2026 | Harian |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 141.645 NS | 31 Mei 2026 | N-PORT |
| TILT · FlexShares Trust | 0,00% | 6.314 NS | 30 April 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 34.873 NS | 30 April 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0,00% | 8.956 NS | 30 April 2026 | N-PORT |
| FSCC · Federated Hermes ETF Trust | 0,00% | 129 NS | 31 Mei 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 3.019 NS | 30 April 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 8.070.274 SH | 8 Agu 2026 | Harian |